Abstract
Thirty-four patients with H2-blocker-resistant reflux esophagitis subsequently healed by 40 mg omeprazole daily entered a maintenance study with 20 mg omeprazole. In 31 evaluable cases the observation period was at least 12 months (mean 24 months). Esophagitis remained in remission in two thirds of patients despite dose reduction. Relapses of esophagitis occurred in 10 cases within six months, which rapidly healed by increasing the omeprazole dose to 40 mg. No further recurrences with 20 mg omeprazole was found later than six months. Peptic strictures primarily requiring repeated dilatation in six patients during healing with omeprazole did not reappear while on omeprazole maintenance. Major side effects that could be attributed to omeprazole were not observed. Gastrin levels remained within or slightly above the normal range in the vast majority. It is concluded that omeprazole maintenance treatment in severe reflux esophagitis is an effective and safe therapy.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Klinkenberg-Knol EC, Jansen JMBJ, Festen HPM, Meuwissen SGM, Lamers CBHW: Double-blind multicentre comparison of omeprazole and ranitidine in the treatment of reflux oesophagitis. Lancet 1:349–351, 1987
Zeitoun P, Desjars de Keranroue N, Isal JP: Omeprazole versus ranitidine in erosive esophagitis. Lancet 2:621–622, 1987
Havelund T, Laursen LS, Skoubo-Kristinasen E, Andersen BN, Pedersen SA, Jensen KB, Fenger C, Hanberg-Sorensen F, Lauritsen K: Omeprazole and ranitidine in treatment of reflux oesophagitis: Double blind comparative trial. Br Med J 296:89–92, 1988
Sandmark S, Carlsson R, Fausa O, Lundell L: Omeprazole or ranitidine in the treatment of reflux esophagitis. Scand J Gastroenterol 23:625–632, 1988
Vantrappen G, Rutgeerts L, Schurmans P, Coengrachts JL: Omeprazole (40 mg) is superior to ranitidine in short-term treatment of ulcerative reflux esophagitis. Dig Dis Sci 33:523–529, 1988
Dammann HG, Blum AL, Lux G, Rehner M, Riecken EO. Schiessel R, Wienbeck M, Witzel L, Berger J: Unterschiedliche Heilungstendenz der Refluxösophagitis nach Omeprazol und Ranitidin. Dtsch Med Wochenschr 111:123–128, 1986
Brunner G, Creutzfeldt W, Harke U, Lamberts R: Therapy with omeprazole in patients with peptic ulcerations resistant to extended high dose ranitidine treatment. Digestion 39:80–90, 1988
Koop H, Hotz J, Pommer G, Klein M, Arnold R: Prospective evaluation of omeprazole treatment in reflux oesophagitis refractory to H2-receptor antagonists. Alim Pharmac Ther 4:593–599, 1990
Hetzel DJ, Dent J, Reed WD, Narielvala FM, MacKinnon M, McCarthy JH, Mitchell B, Beverridge B, Laurence BH, Gibson G, Grant AK, Shearman DJC, Whitehead R, Buckle PJ: Healing and relapse of severe peptic esophagitis after treatment with omeprazole. Gastroenterology 95:903–912, 1988
Koelz HR, Birchler R, Bretholz A, Bron B, Capitaine Y, Delmore G, Fehr HF, Fumagalli I, Gehrig J, Gonvers JJ, Halter F, Hammer B, Kayasseh L, Kobler E, Miller G, Munst G, Pelloni S, Realini S, Schmid P, Voirol M, Blum AL: Healing and relapse of reflux esophagitis during treatment with ranitidine. Gastroenterology 91:1198–1205, 1986
Sontag S, Vlahcevic ZR, Orr W, McCallum RW, Zimmerman T, Behar J, Begun J, Tiffany D, GERD Study Group: Ranitidine versus placebo in long-term treatment of gastroesophageal reflux (GERD). Gastroenterology 88:1595, 1985
Savary M, Miller G: The Oesophagus. Solothurn, Gassmann, 1977
Siewert JR, Ottenjann R, Heilmann K, Neiss A, Döpfer H: Therapie und Prophylaxe der Refluxkrankheit. Teil I: Epidemiologie und Ergebnisse der Schubtherapie. Z Gastroenterol 24:381–395, 1986
Mayer G, Arnold R, Feule G, Fuchs K, Ketterer H, Track NS, Creutzfeldt W: Influence of feeding and sham feeding upon serum gastrin and gastric acid secretion in control subjects and duodenal ulcer patients. Scand J Gastroenterol 9:703–710, 1974
Klinkenberg-Knol EC, Jansen JMBJ, Lamers CBHW, Nelis F, Meuwissen SGM: Temporary cessation of long-term maintenance treatment with omeprazole in patients with H2-receptor antagonist resistant reflux oesophagitis: Effects on symptoms, endoscopy, serum gastrin levels and gastric acid output. Scand J Gastroenterol 25:1144–1150, 1990
Klinkenberg-Knol EC, Meuwisen SGM: Treatment of reflux oesophagitis resistant to H2-receptor antagonists. Digestion 44(suppl 1):47–53, 1989
Jansen JMBJ, Lamers CBHW: Omeprazole in the shortterm treatment of reflux oesophagitis. Digestion 44(suppl 1): 40–46, 1989
Gorbach SL: Infectious diarrhea.In Gastrointestinal Diseases. 4th ed. MH Sleisinger, JS Fordtran (eds). Philadelphia, WB Saunders, 1989, pp 1191–1232
Jansen JMBJ, Klinkenberg-Knol EC, Meuwissen SGM, de Bruijne JW, Festen HPM, Snel P, Lückers AEG, Biemond I, Lamers CBHW: Effect of long-term treatment with omeprazole on serum gastrin and serum group A and C pepsinogens in patients with reflux esophagitis. Gastroenterology 99:621–628, 1990
Lamberts, R, Creutzfeldt W, Stöckmann F, Jacubaschke U, Maas S, Brunner G: Long-term omeprazole treatment in man: Effects on gastric endocrine cell populations. Digestion 39:126–135, 1988
Solcia E, Bordi C, Creutzfeldt W, Dayal Y, Dayan AD, Falkmer S, Gremelius L, Havu N: Histopathological classification of nonantral gastric endocrine growths in man. Digestion 41:185–200, 1988
Koop H, Wachtmann H, Eissele R, Arnold R: Efficacy and safety of long-term maintenance omeprazole therapy in H2-blocker-resistant reflux esophagitis healed by omeprazole. Gastroenterology 98:A70, 1990 (abstract)
Author information
Authors and Affiliations
Additional information
This study was supported by the Deutsche Forschungsgemeinschaft, grant Ko 847/1-4. The skillful technical assistance of Mrs. E. Bothe-Sandfort and Mrs. J. Dionysius is gratefully acknowledged.
Rights and permissions
About this article
Cite this article
Koop, H., Arnold, R. Long-term maintenance treatment of reflux esophagitis with omeprazole. Digest Dis Sci 36, 552–557 (1991). https://doi.org/10.1007/BF01297018
Received:
Revised:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF01297018